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Our aim was to investigate the safety and feasibility of transendocardial
injections guided by 3-dimensional NogaStar XP mapping of autologous bone
marrow-derived mesenchymal stromal cells (MSC) in patients with chronic
myocardial ischemia and left ventricular dysfunction.
The MESAMI 1 trial is a bicentric phase 1 study, including 10 patients
with chronic myocardial ischemia. The inclusion criteria were: NYHA Class
II-IV and/or angina pectoris CCS Class III or IV, chronic ischemic cardiomy-
opathy with LVEF ≤35%, optimal medical and revascularization therapies,
and reversible perfusion defect by SPECT. Bone marrow was obtained by
aspiration from the iliac crest and MSC were expanded in culture for 17 days.
Transendocardial injections (n=14-16) of autologous bone marrow MSC were
made into viable muscle in border zones of left ventricular scar. Bone marrow
volume was 16.8±2.0ml, and patients received 61.5*106 MSC. After 1-month
follow-up (FU), the primary end-point of safety and feasibility was met since
all patients tolerated the procedure with no adverse events due to the proce-
dure and the cell therapy product. Secondary endpoints between baseline and
3-month FU showed a significant decreased of summed stress score measured
by SPECT from 34.1±8 to 25.3±9.5(p<0.05). This effect was not maintained
at 12 months (32.1±8.0, NS). The echocardiographic LVEF improved signifi-
cantly of more than 6% from 29.4±6.5% to 35.9±6.7% (p<0.001) at 3 months
and was maintained up to 12-month FU (35.7±8.1%; p<0.001). Others para-
meters including NYHA, 6-minute walk test, VO2 peak, and Quality of life
(Qol) showed a trend toward improvement at 3 months compared to baseline
and up to 12 months except for Qol.
We demonstrated the safety and the feasibility of this innovative treatment.
A randomized, double blind, multicenter, placebo-controlled clinical trial
(MESAMI 2) will evaluate the efficiency of this procedure in a larger popula-
tion.Clinical Trial Registration: NCT01076920
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Background: Cardiac involvement is frequent in systemic light chain
amyloidosis (AL). Left-sided valvular thickening (LVT) have been described
in AL reflecting heavy infiltration of the valvular endocardium by amyloid
proteins. However, the exact prevalence at diagnosis and the prognostic
significance of LVT in AL patients have never been investigated.
Aims: to study the prevalence and the impact on long-term survival LVT
in AL patients.
Methods and results: Between 1998 and 2013, 150 AL patients were
included at diagnosis (mean age was 68±11 ans, 59% were male). A compre-
hensive transthoracic echocardiography was performed at baseline. The pres-
ence of LVT was assessed visually and was found in 42% of patients. Compared
to patients without LVT, those with LVT have more frequently advanced
NYHA functional class. They also had significantly higher left ventricular (LV)
wall thickening (p=0.01), LV mass (p=0.02), and mitral E/e’ (p=0.0009) and
larger left atrial size (p<0.0001). Moreover, patients with advanced Mayo Clinic
stage more frequently had LVT: 58%, 45%, and 5% in stage III, II, and I respec-
tively (p<0.0001). Patients with severe symptoms more frequently exhibited
LVT (63% in NYHA III-IV vs. 33% in NYHA I-II, p=0.0008). During a mean
follow-up of 2.9±3 years, 79 deaths occurred (53%). The presence of LVT was
significantly associated with reduced 1 and 5-year survival: 51±4% vs. 70±4%
and 32±7% vs. 64±6% respectively (p=0.0002). In multivariate analysis, after
adjustment for age, gender, NYHA class≥III, clearance of creatininemia, and
LV ejection fraction, LVT remained an independant significant marker of mor-
tality (Hazard ratio= 1.9, 95%CI: 1.10-3.34, p=0.02).
Conclusion: The presence of LVT is a common finding in patients with
AL and is associated with impaired both LV systolic and diastolic function,
poorer functional status and advanced stage of the disease. In addition, LVT
appeared as a powerful marker of mortality.
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Objective: To evaluate longitudinal and radial left ventricular (LV) dys-
synchrony in patients with left ventricular hypertrophy (LVH), and to compare
abnormalities associated with hypertrophic cardiomyopathy (HCM) and LVH
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